Looking back (and ahead) at salvage treatment for non-hodgkin lymphoma

ONCOLOGY

Volumn 23, Issue 7, 2009, Pages

  Bierman, Philip J ^a   Armitage, James O ^b  

^a Section of Hematology and Oncology

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; ETOPOSIDE; FOSTAMATINIB; IFOSFAMIDE; IRINOTECAN; MERCAPTOPURINE; PREDNISONE; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; HUMAN; NONHODGKIN LYMPHOMA; NOTE; SALVAGE THERAPY;

HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 67650930410     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. Hernandez-Ilizaliturri FJ, Czuczman MS: Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma (pts 1 and 2). Oncology (Williston Park) 23:546-553, 610-615, 2009.
2. Bierman P, Armitage JO: Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Oncology (Williston Park) 1(9):11-20, 1987.
3. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. The Non Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982.
4. Swerdlow SH, Campos E, Harris NL, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC; Lyon, France; 2008.
5. Hagberg H, Gisselbrecht C: Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 DLBCL followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: An update of the CORAL study. Ann Oncol 17(suppl 4):iv31-iv32, 2006. (Pubitemid 43778973)
6. Miller RA, Maloney DG, Warnke R, et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 316:889-897, 1982. (Pubitemid 12049923)
7. Friedberg JW, Sharman J, Schaefer-Cutillo J, et al: Fostamatinib disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma and chronic lymphocytic leukemia (abstract 3). Blood 112(11):3-4, 2008.
8. Lièvre A, Bachet J-B, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006.
9. Kim DH, Jung HD Kim JG, et al: FC-GR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108:2720-2725, 2006.
10. Habermann TM, Wang SS, Maurer MJ, et al: Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 112:2694-2702, 2008.
11. Rossi D, Rasi S, Franceschetti S, et al: The pharmacogenetic background of the host is an independent predictor of outcome and toxicity in DLBCL treated with R-CHOP21 (abstract 480). Blood 112(11):183, 2008.
12. Horner MJ, Ries LAG, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, Md. Available at http://seer.cancer.gov/csr/1975-2006/. Based on Nov 2008 SEER data submission, posted to the SEER website, 2009.